

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Examiner: To be Assigned
Louis E. BURTON, et al.)	Art Unit: To be Assigned
Application Serial No. To be Assigned)	Parent Serial No. 10/072,681
Filed: Herewith)	Parent Filed: February 8, 2002
For: PURIFICATION OF NGF)	Attorney's Docket No. 39766-0037 C3C1
)	Customer No. 25213

EXPRESS MAIL LABEL NO. EL 977 676 653 US
Date Mailed: FEBRUARY 18, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Patent Application
Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☒ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☒ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:


- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and
- C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. **08-1641 (Attorney's Docket No. 39766-0037 C3C1)**.

Respectfully submitted,

By: 
James A. Fox (Reg. No. 38,455)

Dated: February 18, 2004

HELLER EHRMAN WHITE & McAULIFFE LLP
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000
Customer No. 25213

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

SV 2006472 v1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. To be Assigned
	APPLICANT Louis E. BURTON, et al.	
	FILING DATE Herewith	GROUP To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1 *	4,407,744	04.10.83	Young, D.			
	2 *	4,565,785	21.01.86	Gilbert, et al.			
	3 *	4,673,641	16.06.87	Georgé, et al.			
	4 *	4,710,473	01.12.87	Morris			
	5 *	4,738,921	19.04.88	Belagaje, et al.			
	6 *	4,795,706	03.01.89	Hsiung, et al.			
	7 *	5,082,774	21.01.92	Heinrich, et al.			
	8 *	5,169,762	08.12.92	Gray, A.M., et al.			
	9 *	5,210,185	11.05.93	Delli Valle, et al.			
	10 *	5,235,043	10.08.93	Collins, et al.			
	11 *	5,272,063	21.12.93	Chan, H., et al.			
	12 *	5,288,622	22.02.94	Gray, et al.			
	13 *	5,364,769	15.11.94	Rosenthal, A.			
	14 *	5,389,529	14.02.95	Panayotatos, et al.			
	15 *	5,438,121	01.08.95	Barde, et al.			
	16 *	5,453,361	26.09.95	Yancopoulos, G., et al.			
	17 *	5,488,099	30.01.96	Persson, et al.			
	18 *	5,512,661	30.04.96	Shooter, E.M., et al.			
	19 *	5,606,031	25.02.97	Lile, J., et al.			
	20 *	5,639,664	17.06.97	Iwane, M. et al.			
	21 *	5,702,906	30.12.97	Rosenthal, A.			
	22 *	5,705,617	06.01.98	Persson, H., et al.			
	23 *	5,728,803	17.03.98	Urfer, R., et al.			
	24 *	5,733,875	31.03.98	Martin			
	25 *	5,798,448	25.08.98	Caras, I.W., et al.			
	26 *	5,830,858	03.11.98	Rosenthal, A.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. To be Assigned
	APPLICANT Louis E. BURTON, et al.	
	FILING DATE Herewith	GROUP To be Assigned

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	
	27 *	5,843,914	01.12.98	Johnson, Jr., E., et al.				
FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	28 *	685,490	06.12.95	EPO				
	29 *	450,386 A2	09.10.91	EPO			YES	NO
	30 *	414,151	15.03.95	EPO				
	31 *	121,338	10.10.84	EPO				
	32 *	WO 92/05254	02.04.92	PCT				
	33 *	WO 92/22665	23.12.92	PCT				
	34 *	WO 95/16701	22.06.95	PCT				
	35 *	WO 95/30686	16.11.95	PCT				
	36 *	WO 95/33829	14.12.95	PCT				
EXAMINER INITIAL	Ref. No.	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)						
	37 *	Angeletti, "Nerve Growth Factor from Cobra Venom" <u>Proc. Natl. Acad. Sci. USA</u> 65(3) :668-674 (1970)						
	38 *	Angeletti, et al. "Nerve Growth Factor From Mouse Submaxillary Gland : Amino Acid Sequence" <u>Proc. Natl. Acad. Sci. USA</u> 68(10) :2417-2420 (1971)						
	39 *	Angeletti, et al. "Purification Characterization, and Partial Amino Acid Sequence" <u>Biochem</u> 15 :26-34 (1976)						
	40 *	Barnett, et al., "Physicochemical Characterization of Recombinant Human Nerve Growth Factor Produced in Insect Cells with a Baculovirus Vector" <u>J. of Neurochemistry</u> 57(3) :1052-1061 (1991)						
	41 *	Belew, et al., "Chick Embryo Nerve Growth Factor" <u>Exp. Cell Res.</u> , 167 :550-558 (1986)						
	42 *	Berkmeier, et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB" <u>Neuron</u> 7 :857-866 (November 1991)						
	43 *	Bigon, et al., "Large Scale Purification and Immunological Characterization of Human Placental Nerve Growth" <u>Neurochemical Research</u> 15(12) :1197-1202 (1990)						
	44 *	Bocchini, et al., "The Nerve Growth Factor: Purification as a 30,000-Molecular-Weight Protein" <u>Proc. Natl. Acad. Sci. USA</u> 64 :787-794 (1969)						
	45 *	Bradshaw, "Nerve Growth Factor" <u>Ann. Rev. Biochem.</u> 47 :191-216 (1978)						
	46 *	Bruce, et al., "Production and Characterization of Biologically Active Recombinant Human Nerve Growth Factor" <u>Neurobiology</u> 10 :89-94 (1988)						
	47 *	Buj-Bello, et al., "GDNF Is an Age-Specific Survival Factor for Sensory and Autonomic Neurons" <u>Neuron</u> 15 :821-828 (1995)						
	48 *	Burton, et al., "Activity and Biospecificity of Proteolyzed Forms and Dimeric Combinations of Recombinant Human and Murine Nerve Growth Factor" <u>J. Neurochem.</u> 59(5) : 1937-1945 (1992)						
	49 *	Callegaro, L., et al. "Biological and Immunochemical Properties of Recombinant Human NGF" <u>Trophic Factors and the Nervous System</u> , L. A. Horrocks, et al., New York: Raven Press, Ltd. pps. 75-82 (1990)						

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. To be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Louis E. BURTON, et al.	
		FILING DATE Herewith	GROUP To be Assigned

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)	
	50 *	Chapman, et al., "The Isolation and Characterization of Nerve Growth Factor from the Prostate Gland of the Guinea Pig" <u>European Journal of Biochemistry</u> 115 :347-351 (1981)						
	51 *	De Young, et al., "RhNGF Slow Unfolding is not Due to Proline Isomerization: Possibility of a Cystine Knot Loop-Threading Mechanism" <u>Protein Sci.</u> 5(8) :1554-1566 (1996)						
	52 *	Dicou, et al., "Synthesis of Chimeric Mouse β -Nerve Growth Factor Precursor and Human -Nerve Growth Factor in Escherichia coli: Immunological Properties" <u>Journal of Neuroscience Research</u> 22 :13-19 (1989)						
	53 *	Edwards, et al., "Processing and Secretion of Nerve Growth Factor: Expression in Mammalian Cells with a Vaccinia Virus Vector" <u>Molecular & Cellular Biology</u> 8(6) :2456-2464 (1988)						
	54 *	Ernfors, et al., "Molecular Cloning and Neurotrophic Activities of a Protein With Structural Similarities to Nerve Growth Factor: Developmental and Topographical Expression in the Brain" <u>Proc. Natl Acad. Sci. USA</u> 87 :5454-5458 (July 1990)						
	55 *	Goldstein, et al., "ISOLATION OF HUMAN NERVE GROWTH FACTOR FROM PLACENTAL TISSUE" <u>Neurochemical Research</u> 3 :175-183 (1978)						
	56 *	Hallbook, et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary" <u>Neuron</u> 6 :845-858 (May 1991)						
	57 *	Heinrich, et al., "Nerve Growth Factor (NGF) is Present in Human Placenta and Semen, But Undetectable in Normal and Paget's Disease Blood: Measurements with an Anti-Mouse NGF Enzyme Immunoassay Using a Recombinant Human NGF Reference" <u>Biochemical and Biophysical Research Communications</u> 155(1) :482-486.						
	58 *	Henerson, et al., "GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle" <u>Science</u> 266 :1062-1064 (1994).						
	59 *	Hohn, et al., "Identification and Characterization of a Novel Member of the Nerve Growth Factor/Brain-derived Neurotrophic Factor Family" <u>Nature</u> 344 :339-341 (March 22, 1990)						
	60 *	Ip, et al., "Mammalian Neurotrophin-4: Structure, Chromosomal Localization, Tissue Distribution, and Receptor Specificity" <u>Proc. Natl. Acad. Sci. USA</u> 89 :3060-3064 (April 1992)						
	61 *	Iwai, et al., "Deoxyribonucleic acids and Related Compounds. XXII. Synthesis of Genes for Human Nerve Growth Factor and Its Fused Protein" <u>Chem. Pharm. Bull.</u> 34(11) :4724-4730 (1986)						
	62 *	Jones, et al., "Molecular Cloning of a Human Gene that is a Member of the Nerve Growth Factor Family" <u>Proc. Natl. Acad. Sci. USA</u> 87 :8060-8064 (1990)						
	63 *	Jongstra-Bilen, et al., "The in vitro processing of the NGF Precursors by the γ -subunit of the 7s NGF complex" <u>Molecular Brain Research</u> 5 :159-169 (1989)						
	64 *	Kahle, et al., "The Amino Terminus of Nerve Growth Factor Is Involved in the Interaction with the Receptor Tyrosine Kinase p140 ^{trkA} " <u>Journal of Biological Chemistry</u> 267(32) :22707-22710 (November 15, 1991)						
	65 *	Kaisho, et al., "Cloning and expression of a cDNA encoding an oval human neurotrophic factor" <u>FEBS Letters</u> 266(1,2) : 187-191 (June 1990)						
	66 *	Kanaya, et al., "Synthesis and Secretion of Human Nerve Growth Factor by Saccharomyces Cerevisiae" <u>Gene</u> 83 :65-74 (1989)						
	67 *	Kotzbauer, et al., "Neurturin, a relative of glial-cell-line-derived neurotrophic factor" <u>Nature</u> 384 :467-470 (1996)						
	68 *	Leibrock, et al., "Molecular Cloning and Expression of Brain-Derived Neurotrophic Factor" <u>Nature</u> 341: 149-152 (September 14, 1989)						
	69 *	Lin, et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons" <u>Science</u> 260 :1130-1132 (1993)						
	70 *	Maisano, et al. "SYNTHESIS OF NEW HYDROPHOBIC ADSORBENTS BASED ON HOMOLOGOUS SERIES OF UNCHARGED ALKYL SULPHIDE AGAROSE DERIVATIVES" <u>Journal of Chromatography</u> , 321 :305-317 (1985)						
	71 *	Maisonpierre, et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" <u>Science</u> 247 :1446-1451 (March 23, 1990)						
	72 *	Mobley, et al., "Characterization of Isolation of Proteolytically Modified Nerve Growth Factor" <u>Biochemistry</u> 15 :5543-5552 (1976)						
	73 *	Norrgren, et al., "Release of Nerve Growth Factor by Human Glial Cells in Culture" <u>Experimental Cell Research</u> 130 : 31-39 (1980)						
	74 *	Pantazis, "Nerve Growth Factor Synthesized by Mouse Fibroblast Cells in Culture: Absence of α and γ Subunits" <u>Biochemistry</u> 22 :4264-4271 (1983)						

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO.	APPLICATION NO.
	39766-0037 C3C1	To be Assigned
	APPLICANT Louis E. BURTON, et al.	
	FILING DATE Herewith	GROUP To be Assigned

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	75 *	Rosenthal, et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" <u>Neuron</u> 4: 767-773 (May 1990)					
	76 *	Rusenko, et al., "Interaction of [¹²⁵ I] Nerve Growth Factor with Acidic Proteins" <u>Neurochemical Research</u> 6(3):287-300 (1981)					
	77 *	Saboori, et al., "Nerve Growth Factor: Biosynthetic Products of the Mouse Salivary Glands. Characterization of Stable High Molecular Weight and 32,000-Dalton Nerve Growth Factors" <u>Biochemistry</u> 25:5565-5571 (1986)					
	78 *	Schmelzer, et al., "Biochemical Characterization of Recombinant Human Nerve Growth Factor" <u>Journal of Neurochemistry</u> 59(5):1675-1683 (1992)					
	79 *	Scott, et al., "Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor" <u>Nature</u> 302:538-540 (1983)					
	80 *	Shih, et al., "Mutagenesis Identifies Amino-terminal Residues of Nerve Growth Factor Necessary for Trk Receptor Binding and Biological Activity" <u>Journal of Biological Chemistry</u> 269:27679-27686 (1994)					
	81 *	Suda, et al., "Nerve Growth Factor in Mouse and Rat Serum: Correlation Between Bioassay and Radioimmunoassay Determination" <u>Proc. Natl. Acad. Sci. USA</u> 75(8):4042-4046 (1978)					
	82 *	Ulrich, et al., "Human β -Nerve Growth Factor Gene Sequence Highly Homologous to That of Mouse" <u>Nature</u> 303:821-825 (June 1983)					
	83 *	Ulrich, et al., "Sequence Homology of Human and Mouse B-NGF Subunit Genes" <u>Symp. on Quan. Biol.</u> 48:435-442 (1983)					
	84 *	Urfer, et al., "The Binding Epitopes of Neurotrophin-3 to its Receptors trkC and gp75 and the Design of a Multifunctional Human Neurotrophin" <u>The EMBO Journal</u> 13(24):5896-5909 (1994)					
	85 *	Varon, et al., "The Isolation of the Mouse Nerve Growth Factor Protein in a High Molecular Weight Form" <u>Biochemistry</u> 6(7):2202-2209 (1967)					
	86 *	Walker, et al., "Human Nerve Growth Factor: Lack of Immunocross-activity with Mouse Nerve Growth Factor" <u>Life Sciences</u> 26:195-200 (1980)					

S:\DOCS\JMJM-7922.DOC
060502

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	